Clinical implications of Ezrin and CD44 co-expression in breast cancer

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1899-1905

  Ma, Lifang ^a   Jiang, Tao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; CD44; Chemotherapy resistance; Ezrin; Stem cells; Survival

Indexed keywords

CD24 ANTIGEN; CISPLATIN; DOCETAXEL; EPIRUBICIN; EZRIN; HERMES ANTIGEN; TUMOR MARKER;

ADULT; AGE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; DISTANT METASTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; ANTIGENS, CD24; ANTIGENS, CD44; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882715573     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2641     Document Type: Article

References (19)

1. Dowling EC, Klabunde C, Patnick J and Ballard-Barbash R; International Cancer Screening Network (ICSN): Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen 17: 139-146, 2010.
2. Tsuji W, Teramukai S, Ueno M, Toi M and Inamoto T: Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer: Apr 5, 2012 (Epub ahead of print).
3. Magee JA, Piskounova E and Morrison SJ: Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-296, 2012.
4. Liu C, Cao X, Zhang Y, Xu H, Zhang R, Wu Y, Lu P and Jin F: Co-expression of Oct-4 and Nestin in human breast cancers. Mol Biol Rep 39: 5875-5881, 2012.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
6. Louderbough JM and Schroeder JA: Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res 9: 1573-1586, 2011.
7. Ren L, Hong SH, Chen QR, Briggs J, Cassavaugh J, Srinivasan S, Lizardo MM, Mendoza A, Xia AY, Avadhani N, et al: Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma. Cancer Res 72: 1001-1012, 2012.
8. Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, et al: Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 31: 269-281, 2012.
9. Boldrini E, Peres SV, Morini S and de Camargo B: Immuno-expression of Ezrin and CD44 in patients with osteosarcoma. J Pediatr Hematol Oncol 32: e213-e217, 2010.
10. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270, 2003.
11. Liu W, Rui H, Wang J, Lin S, He Y, Chen M, Li Q, Ye Z, Zhang S, Chan SC, et al: Axin is a scaffold protein in TGF-β signaling that promotes degradation of Smad7 by Arkadia. EMBO J 25: 1646-1658, 2006.
12. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987 (in German).
13. Liu S, Clouthier SG and Wicha MS: Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia 17: 15-21, 2012.
14. Countercurrents Series and Narod SA: A model for breast cancer risk based on stem-cell theory. Curr Oncol 19: 9-11, 2012.
15. Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y, Chen B, Xu H, Jin F and Lu P: Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg 253: 1165-1171, 2011.
16. Gould KL, Bretscher A, Esch FS and Hunter T: cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1. EMBO J 8: 4133-4142, 1989.
17. Hart SP, Rossi AG, Haslett C and Dransfield I: Characterization of the effects of cross-linking of macrophage CD44 associated with increased phagocytosis of apoptotic PMN. PLoS One 7: e33142, 2012.
18. Wang YY, Chen WL, Huang ZQ, Yang ZH, Zhang B, Wang JG, Li HG and Li JS: Expression of the membrane-cytoskeletal linker Ezrin in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112: 96-104, 2011.
19. Hertweck MK, Erdfelder F and Kreuzer KA: CD44 in hematological neoplasias. Ann Hematol 90: 493-508, 2011.